Related Experiment Videos
Oligodendrocyte development and myelination in GFP-transgenic zebrafish
Mika Yoshida1, Wendy B Macklin
1Department of Neurosciences, Lerner Research Institute, The Cleveland Clinic Foundation,Cleveland, Ohio 44195, USA.
Journal of Neuroscience Research
|May 28, 2005
Summary
Researchers developed a transgenic zebrafish line expressing enhanced green fluorescent protein (EGFP) in oligodendrocytes. This tool allows in vivo visualization of myelination and facilitates the discovery of new myelin defects.
Area of Science:
- Developmental Biology
- Neuroscience
- Genetics
Background:
- Green fluorescent protein (GFP) transgenic zebrafish are crucial for visualizing dynamic developmental processes like cell migration.
- Visualizing myelination in vivo and screening for myelin defects requires effective tools for oligodendrocyte study.
Purpose of the Study:
- To investigate the efficacy of zebrafish P0 and mouse proteolipid protein (PLP) promoters in driving GFP expression in zebrafish oligodendrocytes.
- To establish a stable transgenic zebrafish line for in vivo myelination studies.
Main Methods:
- Transient expression assays using zebrafish P0 and mouse PLP promoters driving enhanced GFP (EGFP).
- Establishment and characterization of a stable transgenic zebrafish line, tg(plp:EGFP), expressing EGFP under the mouse PLP promoter.
- Time-lapse confocal microscopy to observe EGFP expression and oligodendrocyte morphology/distribution.
Main Results:
- Both P0 and PLP promoters drove EGFP expression in oligodendrocytes and their precursors transiently.
- The stable tg(plp:EGFP) zebrafish line showed EGFP expression in oligodendrocytes starting at 24 hours postfertilization (hpf).
- EGFP-expressing oligodendrocytes exhibited characteristic morphology and a ventral distribution in the central nervous system by 54 hpf.
Conclusions:
- The tg(plp:EGFP) transgenic zebrafish line is a valuable tool for in vivo observation of normal and abnormal myelination.
- This model system has significant potential for facilitating mutagenesis screens to identify novel dysmyelinating mutants.